TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
33.33
-0.04 (-0.12%)
May 14, 2025, 1:28 PM - Market open
TG Therapeutics Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for TG Therapeutics stock ranges from a low of $22 to a high of $55. The average analyst price target of $40.8 forecasts a 22.41% increase in the stock price over the next year.
Price Target: $40.80 (+22.41%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 4, 2025.
Analyst Ratings
The average analyst rating for TG Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +65.02% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +65.02% | Jan 15, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $30 → $43 | Buy | Maintains | $30 → $43 | +29.01% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $55 | Strong Buy | Maintains | $49 → $55 | +65.02% | Nov 5, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $20 → $22 | Hold | Maintains | $20 → $22 | -33.99% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
601.02M
from 329.00M
Increased by 82.68%
Revenue Next Year
826.23M
from 601.02M
Increased by 37.47%
EPS This Year
0.95
from 0.15
Increased by 532.40%
EPS Next Year
1.99
from 0.95
Increased by 109.37%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 665.1M | 938.5M | 1.2B | ||
| Avg | 601.0M | 826.2M | 1.0B | ||
| Low | 529.1M | 679.1M | 803.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 102.1% | 56.1% | 46.0% | ||
| Avg | 82.7% | 37.5% | 22.7% | ||
| Low | 60.8% | 13.0% | -2.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.46 | 2.68 | 3.15 | ||
| Avg | 0.95 | 1.99 | 2.59 | ||
| Low | 0.43 | 1.03 | 1.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 873.0% | 182.3% | 58.6% | ||
| Avg | 532.4% | 109.4% | 30.3% | ||
| Low | 187.5% | 8.5% | -19.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.